Loading…
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research...
Saved in:
Published in: | Molecular cancer 2010-11, Vol.9 (1), p.305-305 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3 |
---|---|
cites | |
container_end_page | 305 |
container_issue | 1 |
container_start_page | 305 |
container_title | Molecular cancer |
container_volume | 9 |
creator | Gravina, Giovanni L Festuccia, Claudio Marampon, Francesco Popov, Vladimir M Pestell, Richard G Zani, Bianca M Tombolini, Vincenzo |
description | Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein. |
doi_str_mv | 10.1186/1476-4598-9-305 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A244673820</galeid><doaj_id>oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca</doaj_id><sourcerecordid>A244673820</sourcerecordid><originalsourceid>FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEoqVw5oYsOHBKa8dOYl-Qti0flSq4wNly7PGuV4m92Alofwd_uM5uWXVRkQ-2Zt55xvY7RfGa4HNCeHNBWNuUrBa8FCXF9ZPi9BB5-uB8UrxIaY0xaXnLnhcnFSGYt1ycFn8uXejD0mnVo6hGF7zqAdkQ0bgCNCVAwaLrrws0wLja9mNUPlmIKiecX7nOjSEmpBLy8BulnB5hud3VD8FM_Y44I8ZpyLEIaRN8rh0D0isYQm4S1WaLlDe5vXE7_cvimVV9glf3-1nx49PH71dfyttvn2-uFrdl12Ixlk3T4Y5S3HTaMNMq0dUtrajQRlUdY7VqKDYGiBCKUmoZCFvXyrbAWkwwUfSsuNlzTVBruYluUHErg3JyFwhxKVUcne5BQqUwxm3FKdes5kYwoKzWilnONNEz68OetZm6AYwGn_-iP4IeZ7xbyWX4JensCqEZcLkHdC78B3Cc0WGQs8FyNliKDKoz5P39LWL4OUEa5eCShr5XHsKUZHafcMxJk5Vv_1GuwxSz-UkKXFUsK2fcu71omYdCOm9D7qxnpFxUjDUt5RXOqvNHVHkZGJwOHqzL8aOCi32BjiGlCPbwSoLlPNaPvOvNw9896P_OMb0Dsmz1BQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902248745</pqid></control><display><type>article</type><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central Free</source><creator>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</creator><creatorcontrib>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</creatorcontrib><description>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</description><identifier>ISSN: 1476-4598</identifier><identifier>EISSN: 1476-4598</identifier><identifier>DOI: 10.1186/1476-4598-9-305</identifier><identifier>PMID: 21108789</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; DNA methylation ; DNA Modification Methylases - antagonists & inhibitors ; DNA Modification Methylases - metabolism ; Enzyme inhibitors ; Enzyme Inhibitors - therapeutic use ; Epigenesis, Genetic - drug effects ; Health aspects ; Humans ; Medical research ; Methyltransferases ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - radiotherapy ; Physiological aspects ; Proteins ; Radiation, Ionizing ; Radiotherapy ; Review</subject><ispartof>Molecular cancer, 2010-11, Vol.9 (1), p.305-305</ispartof><rights>COPYRIGHT 2010 BioMed Central Ltd.</rights><rights>2010 Gravina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2010 Gravina et al; licensee BioMed Central Ltd. 2010 Gravina et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001713/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/902248745?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21108789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gravina, Giovanni L</creatorcontrib><creatorcontrib>Festuccia, Claudio</creatorcontrib><creatorcontrib>Marampon, Francesco</creatorcontrib><creatorcontrib>Popov, Vladimir M</creatorcontrib><creatorcontrib>Pestell, Richard G</creatorcontrib><creatorcontrib>Zani, Bianca M</creatorcontrib><creatorcontrib>Tombolini, Vincenzo</creatorcontrib><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><title>Molecular cancer</title><addtitle>Mol Cancer</addtitle><description>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</description><subject>Animals</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>DNA methylation</subject><subject>DNA Modification Methylases - antagonists & inhibitors</subject><subject>DNA Modification Methylases - metabolism</subject><subject>Enzyme inhibitors</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Epigenesis, Genetic - drug effects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Medical research</subject><subject>Methyltransferases</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - radiotherapy</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Radiation, Ionizing</subject><subject>Radiotherapy</subject><subject>Review</subject><issn>1476-4598</issn><issn>1476-4598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kk1v1DAQhiMEoqVw5oYsOHBKa8dOYl-Qti0flSq4wNly7PGuV4m92Alofwd_uM5uWXVRkQ-2Zt55xvY7RfGa4HNCeHNBWNuUrBa8FCXF9ZPi9BB5-uB8UrxIaY0xaXnLnhcnFSGYt1ycFn8uXejD0mnVo6hGF7zqAdkQ0bgCNCVAwaLrrws0wLja9mNUPlmIKiecX7nOjSEmpBLy8BulnB5hud3VD8FM_Y44I8ZpyLEIaRN8rh0D0isYQm4S1WaLlDe5vXE7_cvimVV9glf3-1nx49PH71dfyttvn2-uFrdl12Ixlk3T4Y5S3HTaMNMq0dUtrajQRlUdY7VqKDYGiBCKUmoZCFvXyrbAWkwwUfSsuNlzTVBruYluUHErg3JyFwhxKVUcne5BQqUwxm3FKdes5kYwoKzWilnONNEz68OetZm6AYwGn_-iP4IeZ7xbyWX4JensCqEZcLkHdC78B3Cc0WGQs8FyNliKDKoz5P39LWL4OUEa5eCShr5XHsKUZHafcMxJk5Vv_1GuwxSz-UkKXFUsK2fcu71omYdCOm9D7qxnpFxUjDUt5RXOqvNHVHkZGJwOHqzL8aOCi32BjiGlCPbwSoLlPNaPvOvNw9896P_OMb0Dsmz1BQ</recordid><startdate>20101125</startdate><enddate>20101125</enddate><creator>Gravina, Giovanni L</creator><creator>Festuccia, Claudio</creator><creator>Marampon, Francesco</creator><creator>Popov, Vladimir M</creator><creator>Pestell, Richard G</creator><creator>Zani, Bianca M</creator><creator>Tombolini, Vincenzo</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20101125</creationdate><title>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</title><author>Gravina, Giovanni L ; Festuccia, Claudio ; Marampon, Francesco ; Popov, Vladimir M ; Pestell, Richard G ; Zani, Bianca M ; Tombolini, Vincenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>DNA methylation</topic><topic>DNA Modification Methylases - antagonists & inhibitors</topic><topic>DNA Modification Methylases - metabolism</topic><topic>Enzyme inhibitors</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Epigenesis, Genetic - drug effects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Medical research</topic><topic>Methyltransferases</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - radiotherapy</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Radiation, Ionizing</topic><topic>Radiotherapy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gravina, Giovanni L</creatorcontrib><creatorcontrib>Festuccia, Claudio</creatorcontrib><creatorcontrib>Marampon, Francesco</creatorcontrib><creatorcontrib>Popov, Vladimir M</creatorcontrib><creatorcontrib>Pestell, Richard G</creatorcontrib><creatorcontrib>Zani, Bianca M</creatorcontrib><creatorcontrib>Tombolini, Vincenzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecular cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gravina, Giovanni L</au><au>Festuccia, Claudio</au><au>Marampon, Francesco</au><au>Popov, Vladimir M</au><au>Pestell, Richard G</au><au>Zani, Bianca M</au><au>Tombolini, Vincenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation</atitle><jtitle>Molecular cancer</jtitle><addtitle>Mol Cancer</addtitle><date>2010-11-25</date><risdate>2010</risdate><volume>9</volume><issue>1</issue><spage>305</spage><epage>305</epage><pages>305-305</pages><issn>1476-4598</issn><eissn>1476-4598</eissn><abstract>Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase (DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors. These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are inevitable in order to finalize and confirm the consistency of current observations.The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and mechanisms of action for these combined treatments will be discussed herein.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21108789</pmid><doi>10.1186/1476-4598-9-305</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1476-4598 |
ispartof | Molecular cancer, 2010-11, Vol.9 (1), p.305-305 |
issn | 1476-4598 1476-4598 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_e2a00072838c458d94e345ca4f84c1ca |
source | Access via ProQuest (Open Access); PubMed Central Free |
subjects | Animals Cancer Cancer therapies Care and treatment Chemotherapy DNA methylation DNA Modification Methylases - antagonists & inhibitors DNA Modification Methylases - metabolism Enzyme inhibitors Enzyme Inhibitors - therapeutic use Epigenesis, Genetic - drug effects Health aspects Humans Medical research Methyltransferases Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - radiotherapy Physiological aspects Proteins Radiation, Ionizing Radiotherapy Review |
title | Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A07%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20rationale%20for%20the%20use%20of%20DNA%20methyltransferase%20inhibitors%20as%20new%20strategy%20for%20modulation%20of%20tumor%20response%20to%20chemotherapy%20and%20radiation&rft.jtitle=Molecular%20cancer&rft.au=Gravina,%20Giovanni%20L&rft.date=2010-11-25&rft.volume=9&rft.issue=1&rft.spage=305&rft.epage=305&rft.pages=305-305&rft.issn=1476-4598&rft.eissn=1476-4598&rft_id=info:doi/10.1186/1476-4598-9-305&rft_dat=%3Cgale_doaj_%3EA244673820%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b709t-66b0b3306bcd4d7a9b573239cda2b445a630dde199a333f4e9f55af7e470101a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=902248745&rft_id=info:pmid/21108789&rft_galeid=A244673820&rfr_iscdi=true |